A review of exenatide as adjunctive therapy in patients with type 2 diabetes

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 219-240

  Robles, Gisela I ^a   Singh Franco, Devada ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Exenatide; Gastric emptying; Glucagon; Glucagon like peptide 1; Incretin; Pharmacodynamics; Pharmacoeconomic; Pharmacokinetics; Postprandial hyperglycemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIEMETIC AGENT; C PEPTIDE; CHLORPROPAMIDE; DIGOXIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; PARACETAMOL; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; WARFARIN;

ABDOMINAL PAIN; ACUTE HEMORRHAGIC PANCREATITIS; ANOREXIA; AREA UNDER THE CURVE; BEDTIME DOSAGE; BLEEDING; BODY WEIGHT; BOLUS INJECTION; CELL FUNCTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIET THERAPY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE PRURITUS; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SATIETY; SIDE EFFECT; STOMACH EMPTYING; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77950637951     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s3321     Document Type: Review

References (52)

1. National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. http://diabetes.niddk.nih.gov/dm/pubs/staTIStics/ DM-Statistics.pdf. Accessed January 3rd, 2009.
2. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413-420. (Pubitemid 39281877)
3. American Diabetes Association. Direct and indirect costs of diabetes in the United States. http://www.diabetes.org/diabetes-statistics/cost-of-diabetes- in-us.jsp. Accessed January 3rd, 2009.
4. Wild S, Roglic G, Green A, et al. Global Prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
5. American Diabetes Association. Standards of Medical Care. Diabetes Care. 2009;32(S1):S13-S61.
6. Cook CL, Johnson JT, Wade WE. Diabetes Mellitus. In: Chisholm-Burns M Wells BG, Schwinghammer TL, et al. editors. Pharmacotherapy, Principles and Practice.1st ed. New York, NY: McGraw-Hill; 2008. p. 643-666.
7. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110. (Pubitemid 36042113)
8. Van Gaal LF, De LI. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia. 2003;46:M44-M50. (Pubitemid 36543103)
9. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate gycemic control? Eur J Endocrinol. 2008;158:773-784.
10. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053-4059. (Pubitemid 32055352)
11. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinant of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-3723. (Pubitemid 32755966)
12. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296:E415-E421.
13. Kim W, Egan JM. The role of incretins in glucose homestasis and diabetes treatment. Pharmacol Rev. 2008;60:470-512.
14. Joy SV, Rodgers PT, Scates AC. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother. 2005,39:110-118. (Pubitemid 40052386)
15. Nielsen L, Young A, Parkes D. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides. 2004;117:77-88. (Pubitemid 38045329)
16. Xu G, Kaneto H, Lopez-Avalo MD, et al. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006;73:107-110. (Pubitemid 43765553)
17. Movassat J, Beattie GM, Lopez AD, et al. Exendin4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab. 2002;87:4775-4781. (Pubitemid 35247075)
18. Liu Z, Habener JF. Glucagon-likePeptide-1 activation of TCF7L2- dependent wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283:8723-8735.
19. Chen J, Couto F, Minn AH, et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophy Res Comm. 2006;346:1067-1074. (Pubitemid 43913716)
20. Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals, Inc; 2008.
21. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagons-like peptide 1 in vitro and in vivo by depeptidyl peptidase IV. Endocrinol. 1995;136:3585-3596.
22. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetcs of exenatide. Br J Clin Pharmacol. 2007;64: 317-327. (Pubitemid 47283860)
23. Blase E, Taylor K, Gao H, et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005;45:570-577. (Pubitemid 40562948)
24. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45:1032-1037. (Pubitemid 41192362)
25. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46:1179-1187. (Pubitemid 44387418)
26. Bunck MC, Diamant M, Corner A. One-year treatment with exenatide improves beta-cell function compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care. 2009;32:762-768.
27. Fehse F, Trautman M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997. (Pubitemid 41606516)
28. Linnebjerg H, Kothare PA, Skivanekt A, et al. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med. 2006;23:240-245.
29. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294:E846-E852.
30. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082-3089.
31. Linnebjerg H, Park S, Kothare P, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-129.
32. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719-2725. (Pubitemid 36733545)
33. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22: 1143-1999. (Pubitemid 29293967)
34. Moretto TJ, Milton DR, Ridge TD, et al. Eff icacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: A randomized, doubleblind, placebo-controlled, parallel-group study. Clin Ther. 2008;30: 1448-1460.
35. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.
36. Buse JB, Henry RR, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635. (Pubitemid 39441462)
37. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28:1092-1100. (Pubitemid 40616618)
38. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091. (Pubitemid 40616617)
39. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447. (Pubitemid 44349236)
40. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419-428. (Pubitemid 44349234)
41. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29:139-153.
42. Elkind-Hirsch K, Marrioneaux O, Bhushan M, et al. Comparison of single and combined treatment with exenatide and metformin on mestrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:2670-2678. (Pubitemid 352008535)
43. Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. The Annals of Pharmacotherapy. 2008;42:1541-1551.
44. Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinediones in suboptimally controlled type 2 diabetes. Ann Intern Med. 2007;146:477-485. (Pubitemid 351650556)
45. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med. 2005;143:559-569. (Pubitemid 41476552)
46. Boye KS, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006;4:80. (Pubitemid 44698228)
47. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267.
48. Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin. 2008;24:639-644.
49. Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411-417. (Pubitemid 39302967)
50. U.S. Food and Drug Administration. Postmarketing reviews: Byetta and acute pancreatitis. FDA Drug Safety Newsletter. 2008;1(2).
51. Byetta (exenatide). In: Fleming T, Murray L, editors. Drug Topics Redbook. Montvale, NJ: Thomson PDR; 2009.
52. Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health. 2008; 11:22-33.